Patient | MC1 (mGy) | MC2 (mGy) | gMC3 (mGy) | SMIRD (mGy) |
---|
P8 | 1123 | 225 | 718 | 46 |
P9 | 684 | 202 | 408 | 40 |
- gMC3 uses the patient-specific Tc-99m-anti-granulocyte-based active bone marrow VOI. MC1 assumes a physiological active bone marrow distribution, while MC2 assumes a physiological distribution, however with displacement of active bone marrow from the direct site of metastases